Grapiprant clinical trials
Also written CJ-023,423, AAT-007 and RQ-00000007.
How each study uses grapiprant is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2012 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 4
Arrys Therapeutics (2) · Applied Therapeutics, Inc. (1) · NYU Langone Health (1) · University of Kentucky (1) · Alltech Life Sciences Inc. (1) · Pfizer (1) · M.D. Anderson Cancer Center (1) · University of Maryland, Baltimore (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses grapiprant is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast CancerTerminatedPhase 1/2M.D. Anderson Cancer CenterNCT05041101Written as Grapiprant
- Grapiprant and Pembrolizumab in Patients With Advanced or Progressive MSS Colorectal CancerCompletedPhase 1Arrys TherapeuticsNCT03658772Written as grapiprant
- Safety and Efficacy of AT-001 in Patients With Diabetic CardiomyopathyActive, not recruitingPhase 3Applied Therapeutics, Inc.NCT04083339Written as AT-001
- Cardiovascular Effects of COVID-19CompletedPhase 2NYU Langone HealthNCT04365699Written as AT-001
- Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC AdenocarcinomaTerminatedPhase 1/2Arrys TherapeuticsNCT03696212Written as grapiprant and pembrolizumab
- Phase II Trial of EP4 Receptor Antagonist, AAT-007 (RQ-07; CJ-023,423) in Advanced Solid TumorsWithdrawnPhase 2University of Maryland, BaltimoreNCT02538432Written as RQ-00000007
- AT-001 for Long-term Preservation of Brain Health in AgingCompletedNot applicableUniversity of KentuckyNCT03062384Written as AT-001
- Safety and Tolerability of Antioxidant (AT-001)for Reducing Brain Oxidative StressCompletedPhase 1Alltech Life Sciences Inc.NCT01731093Written as AT-001
- A Study Of The Effect Of CJ-023,423 On The Incidence Of Stomach UlcersCompletedPhase 1PfizerNCT00392080Written as CJ-023,423
Codes
What other systems call grapiprant · ClinicalTrials.gg INT005154
- MeSH (NLM) C522837grapiprantOne source NLM
- UNII (FDA) J9F5ZPH7NBGRAPIPRANTConfirmed FDA, NLM, Wikidata
- RxNorm 1862951Confirmed FDA, Wikidata
- Wikidata Q27077852grapiprantConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C124131GrapiprantOne source FDA
- DrugBank DB12836One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C522837 | grapiprant | One source NLM |
| UNII (FDA) | J9F5ZPH7NB | GRAPIPRANT | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1862951 | — | Confirmed FDA, Wikidata |
| Wikidata | Q27077852 | grapiprant | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C124131 | Grapiprant | One source FDA |
| DrugBank | DB12836 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.